This study indicated that salidroside defends against NAFLD by alleviating hepatic lipid metabolism, reducing the release of inflammatory factors, and inhibiting NLRP3 inflammasome activation in vivo and in vitro, which were related to the regulation of the TXNIP/NLRP3 pathways (Zheng et al., 2018). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.